Expression of CD133 in endometrial cancer cells and its implications

Cancer stem cells are an attractive therapeutic target for cancer. The present study examined stem cell characteristics of CD133+ cells isolated from endometrial cancer. Phenotypic characteristics, proliferation, migration, anchorage-independent growth, chemoresistance, gene expression profile and tumorigenicity of CD133+ tumor cells were assessed. Primary tumor exhibited immunoreactivity for CD133. Endometrial CD133+ tumor cells enhanced proliferation rate, colony formation, chemotaxis migration ability, and chemoresistance to cisplatin, paclitaxel, and doxorubicin than CD133- cells. CD133+ cells expressed more cancer stem cells markers such as EpCAM, aldehyde dehydrogenase 1 and insulin-like growth factor-1 receptor than CD133- cells. Moreover, CD133+ cells also increased expression of embryonic stem cell markers including oct4, nanog, sox2, and cmyc than CD133- cells. Finally, CD133+ tumor cells could generate xenograft but not CD133- tumor cells. CD133 and Ki67 were extensively expressed in the xenograft. In conclusion, endometrial CD133+ tumor cells displayed cancer stem cell characteristics and might represent a valuable tool for identifying endometrial cancer stem cells and hence a potential therapeutic target.

• Publication year

  2017

• Venue

  Journal of Cancer

• Publication date

  2017-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.7150/jca.18869PMID 28819416PMCID 5559977
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells

  2018cited by this paper
• Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis

  2016cited by this paper
• Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity

  2016cited by this paper
• Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base.

  2016cited by this paper
• Concise Reviews : Targeting Cancer Stem Cells Using Immunologic Approaches

  2015cited by this paper
• A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms.

  2015cited by this paper
• Proliferative and signaling activities of insulin analogues in endometrial cancer cells.

  2015cited by this paper
• Common stemness regulators of embryonic and cancer stem cells.

  2015cited by this paper
• Molecular characterization of CD133+ cancer stem-like cells in endometrial cancer.

  2014cited by this paper
• CD133-positive cancer stem cells from Colo205 human colon adenocarcinoma cell line show resistance to chemotherapy and display a specific metabolomic profile

  2014cited by this paper
• Proliferation and enrichment of CD133(+) glioblastoma cancer stem cells on 3D chitosan-alginate scaffolds.

  2014cited by this paper
• Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.

  2014cited by this paper
• Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells

  2012cited by this paper
• Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome.

  2011cited by this paper
• Enhanced differentiation and clonogenicity of human endometrial polyp stem cells.

  2011cited by this paper
• Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer.

  2010cited by this paper
• Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents

  2010cited by this paper
• Aldehyde Dehydrogenase 1 A1–Positive Cell Population Is Enriched in Tumor-Initiating Cells and Associated with Progression of Bladder Cancer

  2010cited by this paper
• Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)

  2010cited by this paper
• Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.

  2010cited by this paper
• Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells

  2010cited by this paper
• Treatment Resistance in Stem Cells and Breast Cancer

  2009cited by this paper
• Cells with Characteristics of Cancer Stem/Progenitor Cells Express the CD133 Antigen in Human Endometrial Tumors

  2009influential reference
• ALDH1A1 Is a Marker for Malignant Prostate Stem Cells and Predictor of Prostate Cancer Patients’ Outcome

  2009cited by this paper
• Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells

  2009cited by this paper
• Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer

  2009cited by this paper
• Expression of CD133 on leukemia-initiating cells in childhood ALL.

  2009cited by this paper
• Identification and expansion of the tumorigenic lung cancer stem cell population

  2008cited by this paper
• CD133: molecule of the moment

  2008cited by this paper
• New aspects of adjuvant therapy in endometrial cancer: current standards and future directions.

  2008cited by this paper
• Identification of surface markers for prospective isolation of human endometrial stromal colony-forming cells.

  2008cited by this paper
• Identification and expansion of human colon-cancer-initiating cells

  2007cited by this paper
• Human cord blood CD133+ cells immunoselected by a clinical‐grade apparatus differentiate in vitro into endothelial‐ and cardiomyocyte‐like cells

  2007cited by this paper
• Expression of CD133-1 and CD133-2 in ovarian cancer

  2007cited by this paper
• Cancer stem cells and oncology therapeutics

  2007cited by this paper
• A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

  2007cited by this paper
• Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

  2006cited by this paper
• Brain tumour stem cells

  2006cited by this paper
• Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer

  2005cited by this paper
• Prospective identification of tumorigenic prostate cancer stem cells.

  2005cited by this paper
• Signaling mechanisms for regulation of chemotaxis

  2005cited by this paper
• Clinical isolation and functional characterization of cord blood CD133+ hematopoietic progenitor cells

  2004cited by this paper
• Prospective identification of tumorigenic breast cancer cells

  2003cited by this paper
• Identification of a cancer stem cell in human brain tumors.

  2003cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells

  1998cited by this paper
• Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells.

  1998cited by this paper
• Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

  1997cited by this paper
• AC133, a novel marker for human hematopoietic stem and progenitor cells.

  1997cited by this paper
• Growth Factors in Human Ovarian Follicle Fluid and Growth Factor Receptors in Granulosa-Luteal Cells

  1995cited by this paper
• A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

  1994cited by this paper
• Relationship between surgical‐pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study

  1991cited by this paper

• PAX2 induces endometrial cancer by inhibiting mitochondrial function via the CD133—AKT1 pathway

  2025cites this paper
• Fueling the Seed: Growth Factors and Cytokines Driving Cancer Stem Cells in Gynecological Malignancies

  2025cites this paper
• Prognostic factors and survival of patients with endometrial cancer: A 10-year retrospective cohort study in a tertiary referral center in Northern Taiwan

  2025cites this paper
• Is There Any Difference in Stem Cell Population between Type I and Type II Endometrial Cancer? A Pilot Study

  2025cites this paper
• Influence of Aldehyde Dehydrogenase Inhibition on Stemness of Endometrial Cancer Stem Cells

  2024cites this paper
• MAPK14/p38α shapes the molecular landscape of endometrial cancer and promotes tumorigenic characteristics.

  2024cites this paper
• Experience in creating primary cultures of endometrial cancer and studying cells carrying phenotype of cancer stem cells

  2024cites this paper
• Bone Marrow Mesenchymal Stem Cells Promote Ovarian Cancer Cell Proliferation via Cytokine Interactions

  2024cites this paper
• Phenotypic characteristics of recurrence and metastasis of endometrial epithelial tumors A critical review

  2023cites this paper
• The Diminishment of Novel Endometrial Carcinoma-Derived Stem-like Cells by Targeting Mitochondrial Bioenergetics and MYC

  2022cites this paper
• Additional evidence to support OCT-4 positive VSELs and EnSCs as the elusive tissue-resident stem/progenitor cells in adult mice uterus

  2022cites this paper
• Bone Marrow-Derived Cells in Endometrial Cancer Pathogenesis: Insights from Breast Cancer

  2022cites this paper
• Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?

  2022cites this paper
• Molecular Insights into Endometrial Cancer in Mice

  2022cites this paper
• Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy

  2022cites this paper
• Nanopore Sequencing Reveals Global Transcriptome Signatures of Mitochondrial and Ribosomal Gene Expressions in Various Human Cancer Stem-like Cell Populations

  2021cites this paper
• ETS-Domain Transcription Factor Elk-1 Regulates Stemness Genes in Brain Tumors and CD133+ BrainTumor-Initiating Cells

  2021cites this paper
• Role of Syndecan-1 in Cancer Stem Cells

  2021cites this paper
• CD133 Expression in the Nucleus Is Associated with Endometrial Carcinoma Staging and Tumor Angioinvasion

  2021cites this paper
• Komórki CD133 w raku błony śluzowej trzonu macicy CD133 cells in endometrial cancer

  2020influential citation
• Targeting Endometrial Cancer Stem Cell Activity with Metformin Is Inhibited by Patient-Derived Adipocyte-Secreted Factors

  2019cites this paper
• Differential gene expression induced by Verteporfin in endometrial cancer cells

  2019cites this paper
• of Regenerative Medicine CD133 Clinical Trials: Safety and Efficacy

  2019cites this paper
• Expression Profiles of the Phosphatase and Tensin Homolog (PTEN), CDH1, and CDH2 Genes, and the Cell Membrane Protein, CD133, in the Ishikawa Human Endometrial Adenocarcinoma Cell Line

  2019cites this paper
• ALDH-Dependent Glycolytic Activation Mediates Stemness and Paclitaxel Resistance in Patient-Derived Spheroid Models of Uterine Endometrial Cancer

  2019cites this paper
• Modulation of tumor stem cell characteristics by 17β-estradiol in human mesenchymal stem cells derived from ovarian endometrioma.

  2019cites this paper
• High expression of HMBOX1 contributes to poor prognosis of gastric cancer by promoting cell proliferation and migration.

  2019cites this paper
• Current Options and Future Directions in Immune Therapy for Glioblastoma

  2018cites this paper
• Cancer Stem Cells are Regulated by STAT3 Signalling in Wilms Tumour

  2018cites this paper